Pamrevlumab

Generic Name: Pamrevlumab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 946415-13-0

Unique Ingredient Identifier: QS5F6VTS0O

Background: Pamrevlumab is under investigation in clinical trial NCT00913393 (Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

An Open-label, Randomized, Parallel-arm Study Investigating the Efficacy and Safety of Intravenous Administration of Pamrevlumab Versus Standard of Care in Patients With COVID-19

Phase 2

Completed

Conditions: COVID-19 Respiratory Infection
COVID-19 Pneumonia
Covid19

Interventions: Drug: Pamrevlumab

First Posted Date: 2022-03-02

Last Posted Date: 2022-03-02

Lead Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Target Recruit Count: 42

Registration Number: NCT05262309

Locations: 🇮🇹
Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Roma, Italy

Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD

Phase 3

Terminated

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: Pamrevlumab
Drug: Placebo
Drug: Corticosteroids

First Posted Date: 2020-11-17

Last Posted Date: 2024-08-26

Lead Sponsor: FibroGen

Target Recruit Count: 73

Registration Number: NCT04632940

Locations: 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸
University of California San Diego Health, San Diego, California, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

and more 49 locations

Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease

Phase 2

Terminated

Conditions: COVID-19

Interventions: Drug: Placebo
Drug: Pamrevlumab

First Posted Date: 2020-06-16

Last Posted Date: 2022-07-18

Lead Sponsor: FibroGen

Target Recruit Count: 22

Registration Number: NCT04432298

Locations: 🇺🇸
Research Center, Philadelphia, Pennsylvania, United States

Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Phase 3

Terminated

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Placebo
Drug: Pamrevlumab

First Posted Date: 2020-06-05

Last Posted Date: 2024-08-12

Lead Sponsor: FibroGen

Target Recruit Count: 372

Registration Number: NCT04419558

Locations: 🇳🇱
Longarts - Opleider Longziekten Zuyderland MC, Heerlen, Netherlands
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇬🇧
University College London, London, United Kingdom

and more 154 locations

Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)

Phase 3

Terminated

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: Placebo
Drug: Pamrevlumab
Drug: Corticosteroids

First Posted Date: 2020-05-01

Last Posted Date: 2024-03-12

Lead Sponsor: FibroGen

Target Recruit Count: 98

Registration Number: NCT04371666

Locations: 🇺🇸
Rare Disease Research, LLC, Atlanta, Georgia, United States
🇺🇸
Kennedy Krieger Institute, Baltimore, Maryland, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

and more 50 locations

Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Phase 3

Terminated

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Placebo
Drug: Pamrevlumab

First Posted Date: 2019-05-17

Last Posted Date: 2024-03-19

Lead Sponsor: FibroGen

Target Recruit Count: 356

Registration Number: NCT03955146

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States

and more 122 locations

Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Phase 2

Terminated

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: Pamrevlumab

First Posted Date: 2015-11-17

Last Posted Date: 2024-08-27

Lead Sponsor: FibroGen

Target Recruit Count: 21

Registration Number: NCT02606136

Locations: 🇺🇸
University of California San Francisco - Benioff Children's Hospital, San Francisco, California, United States
🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸
Rare Disease Research, Atlanta, Georgia, United States

and more 7 locations

Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Phase 2

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Placebo
Drug: Pamrevlumab

First Posted Date: 2013-07-01

Last Posted Date: 2020-09-04

Lead Sponsor: FibroGen

Target Recruit Count: 160

Registration Number: NCT01890265

Locations: 🇺🇸
Pensacola Research Consultants, Inc., d.b.a. Avanza Medical Research Center, Pensacola, Florida, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States
🇦🇺
Concord Repatriation, Concord, New South Wales, Australia

and more 39 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy